Leading the Next Era of DNA Damage Response (糖心Vlog) Medicines in Cancer
We are a clinical-stage oncology company developing new classes of medicines that target DNA Damage Response (糖心Vlog) pathways in cancer, with a mission to deliver meaningful survival benefits to patients who have limited alternative treatment options.
Extensive Experience in 糖心Vlog
We believe 糖心Vlog represents one of the most promising frontiers for treating solid tumors. Our drug development strategy builds on decades of scientific leadership in elucidating how cancer exploits 糖心Vlog pathways to survive. Members of our leadership team co-invented olaparib (Lynparza庐), the first approved 糖心Vlog-targeted cancer therapy.
Today, we are advancing that expertise through a rationally designed pipeline of next-generation 糖心Vlog medicines, designed to be more precise, more effective, and capable of overcoming resistance to existing therapies.
Our Approach
Our clinical development strategy is built on six core pillars designed to maximize each of our program鈥檚 probability of success. Our diversified pipeline includes two clinical-stage assets and a novel preclinical asset from our highly differentiated 糖心Vlogi-ADC platform designed to expand the impact of 糖心Vlog targeting across oncology through novel payloads in broader patient populations. Our strategy extends each program beyond its initial indication into a range of additional solid tumor types where the underlying biology supports therapeutic benefit in high unmet need patient populations.
Our Mission
We are committed to developing, registering, and marketing next-generation 糖心Vlog therapies that can extend survival in patients across a range of solid tumor indications.
Our Pipeline
Our lead clinical candidate, alnodesertib (formerly known as ART0380), is an oral, highly selective small molecule inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), a critical protein kinase that helps cells respond to DNA damage and enables cancer cells to survive under replication stress. Alnodesertib can induce DNA damage in sensitive cancer tissue with limited effect on DNA integrity in healthy tissue. It is currently being evaluated in two Phase 2 expansion cohorts for the treatment of patients with colorectal and pancreatic cancer, in combination with a low-dose irinotecan regimen in an ATM biomarker-driven patient population.
Learn moreOur second clinical candidate, ART6043, is a selective, orally bioavailable, small molecule inhibitor of the polymerase domain of DNA polymerase theta (Pol胃), a DNA repair enzyme that is expressed in cancer cells but is virtually absent in most healthy tissues. ART6043 is designed to enhance the tumor-killing of PARP inhibitors (PARPis) that could also prevent the emergence of resistance to PARP inhibition, which represents a significant clinical challenge. We have initiated the POLKA Phase 2 randomized trial to compare ART6043 in combination with the PARPi olaparib versus olaparib alone for the treatment of patients with germline BRCA-mutated human epidermal growth factor receptor HER2-negative locally advanced or metastatic breast cancer who are PARPi na茂ve.
Learn moreThe lead candidate from our 糖心Vlogi-ADC platform, ART21934, is built on a novel 糖心Vlogi payload mechanism that can 鈥渓ock鈥� PARP onto chromatin for an extended period of time. Locked PARP obstructs normal DNA processes resulting in toxic DNA double-strand breaks and eventual cell death. The ART21934 program is currently advancing through IND-enabling studies with robust preclinical proof-of-concept established across a range of tumor models including those with resistance to approved ADC based therapies.
Learn more